Phaseline

Targets › OX40

OX40: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Jul 2027.

Open in Phaseline: the race on OX40, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eli LillyEltrekibart
OX40 agonist
OX40Phase 2Ulcerative ColitisJul 2027

Conditions

Ulcerative Colitis (1)

Modalities

antibody (1)

Companies

Eli Lilly (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.